Sunday, August 19, 2018
 
 
Company News: Page (1) of 1 - 03/13/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Direct-To-Consumer (DTC) Genetic Testing Market is Expected to Grow at The CAGR of 19.4% During 2018-2026: Credence Research

(March 13, 2018)

CredenceResearch.com has Published New Research Report Title “Direct-To-Consumer (DTC) Genetic Testing Market By Sales Channel (Online Sales, OTC Sales, Doctor’s Office), By Business Model (Genome Data Bank Material Model, Individual Health Planning Model, Comprehensive Genome Tests Model, Medical Precision Tests Model, Restricted Trait Tests Model) - Growth, Future Prospects And Competitive Analysis, 2018 – 2026”

SAN JOSE, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- According to the latest report published by Credence Research, Inc. “Direct-to-Consumer (DTC) Genetic Testing Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global direct-to-consumer genetic testing market was valued at US$ 117.1 Mn in 2017 and expected to reach US$ 611.2 Mn by 2026, expanding at a CAGR of 19.4% from 2018 to 2026.

Market Insights

The global Direct-to-Consumer (DTC) genetic testing market is projected to surge with a double digit CAGR of 19.4% during the forecast period from 2018 to 2026. Rising awareness about genome testing and risk of genetic diseases and increased inquisitiveness about the assessment of lineage and ancestry are the major driving factors for the global market. Over the past 10 years, the global DTC genetic testing market has experienced extensive variations in term of market value due to the regulatory constraints. With rampant commercialization of DTC genetic testing products in the U.S., the market was going to be established until FDA ordered the manufacturers to withdraw the products owing to potential health consequences of test generated results. However, with the revived approval of these products, supported by validating data from the market players in 2015, the DTC genetic testing market is estimated to experience lucrative growth during the forecast period.

Based on the sales channel, the global direct-to-consumer genetic testing market is segmented into on-line sales, OTC sales, and doctor’s office. DTC genetic testing market sales are predominantly driven by on-line sales, wherein the products are made available for sale via the internet. Such products are available through manufacturers’ online portals thus ensuring a vast outreach across boundaries. According to the analysis, on-line sales segment dominated the market in 2017 and expected to retain its dominance during the forecast period.

Based on the business model, the global direct-to-consumer genetic testing market is segmented into genome data bank material, individual health planning, comprehensive genome tests, medical precision tests and restricted trait tests. The currently available DTC services include testing for ancestry data with information related to family lineage, identification of health risks and risk of acquiring hereditary diseases, information pertaining to genomic pattern and knowledge of personal traits. In terms of market value, genome data bank material model dominated the global DTC genetic testing market in 2017 and expected to witness perpetual lead throughout the forecast period.

Browse Full Report ,TOC, Tables And Figures @ http://www.credenceresearch.com/report/direct-to-consumer-genetic-testing-market

Based on the geographical demarcation, North America led the global DTC genetic testing market in 2017 with a market share of over 45%. Increasing awareness about the risk of genetic diseases and growing proactive tendency among the public about prevention and efficient management of chronic diseases mainly drive the North America market. Additionally, inquisitiveness about knowledge of lineage also prominently determine the significant sales in this region. Furthermore, Asia Pacific is estimated to be the fastest growing regional market during the forecast period, growing at a CAGR of above 20%. The growth of this region is mainly attributed to rapid evolution of healthcare infrastructure and increasing awareness about the availability of such tests kits. Key market players in the global DTC genetic testing market include deCODE genetics, Inc., Color Genomics, Inc., Gene By Gene, Ltd., Ancestry.com, Inc., Myriad Genetics, Inc., Genleven Oy, 23andMe, Inc., and CENTOGENE AG.

More Reports From This Category:

Biopsy Devices Market

Ostomy Drainage Bags Market

Breast Biopsy Devices Market

Medical Imaging Equipment Market

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact:

Name: Chris Smith

Designation: Global Sales Manager

E-mail: [email protected]

Ph: 1-800-361-8290

Web:  Credence Research

Blog: http://www.mobilecomputingtoday.co.uk/7505/direct-consumer-dtc-genetic-testing-market-growing-double-digit-cagr-credence-research/


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Cancer
  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines